CN202637699U - Carrier for placing radioactive drug in internal radiation therapy - Google Patents
Carrier for placing radioactive drug in internal radiation therapy Download PDFInfo
- Publication number
- CN202637699U CN202637699U CN 201220149394 CN201220149394U CN202637699U CN 202637699 U CN202637699 U CN 202637699U CN 201220149394 CN201220149394 CN 201220149394 CN 201220149394 U CN201220149394 U CN 201220149394U CN 202637699 U CN202637699 U CN 202637699U
- Authority
- CN
- China
- Prior art keywords
- carrier
- radiopharmaceutical
- shell
- place
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Radiation-Therapy Devices (AREA)
Abstract
The utility model discloses a carrier for placing radioactive drug in the internal radiation therapy, which comprises at least one drug carrying body, a housing and an end cover, wherein the drug carrying body is used for placing the radioactive drug; the housing is used for accommodating the drug carrying body; an opening is formed at one end of the housing; the end cover is used for sealing the opening; and at least one of the drug carrying body, the housing and the end cover is made of a medical biodegradable material. The carrier for placing the radioactive drug in the internal radiation therapy, which is disclosed by the utility model, is also gradually degraded when the radioactive drug releases rays at the focus position; and after the radioactive drug completes releasing the rays, the carrier is continuously degraded until the carrier disappears in a human body. Moreover, the number of seed sources (the drug carrying bodies to which the radioactive drug is attached) can be randomly increased and decreased according to the treatment requirements in the housing of the carrier for placing the radioactive drug in the internal radiation therapy; the drug application unit is flexible to regulate; the times that the carrier is implanted into the focus and the number of the housing also cannot be increased; the operating speed is accelerated; and the intraoperative and post-operative loads of a patient are reduced.
Description
Technical field
This utility model relates to field of medicaments, particularly places radiopharmaceutical carrier in a kind of interior radiotherapy.
Background technology
At present, the medication of hospital when radiotherapy generally is divided into two kinds of outer radiotherapy and interior radiotherapies.So-called outer radiotherapy is to realize treating by a kind of main equipment that discharges gamma ray.Radiotherapy in so-called is that radiopharmaceutical is closely shone focus by specific means, thereby realizes the treatment to patient's focus.Above-mentioned radiopharmaceutical is generally iodine I
125Sealed seed source or iodine I
131Sealed seed source etc.
Existing sealed seed source comprises a Titanium shell, is equipped with the seed source in this Titanium shell.This Titanium shell is a complete hermetically-sealed construction, and the surface is without any seam.Described seed source is by being coated with iodine I
125Filamentary silver consist of.According to the requirement of State Food and Drug Administration to the safety of seed source, GB4075-83 must can be born in the seed source---stipulate in " sealed radioactive source classification " standard: 5 grades of (600 ℃ ,-40 ℃) tests of temperature; 3 grades of (25Kpa, 2.0Mpa) tests of pressure; And impact 1 meter freely falling body of 2(50g weight and impact) test.
With iodine I
125The sealed seed source medicine is example, through the iodine I after the sterilization
125Sealed seed source is implanted to patient's intralesional by specific implantation device with it.Through after several half-life, iodine I
125The sealed seed source medicine has not just had the treatment use, but iodine I
125Unless the Titanium shell of sealed seed source utilizes modus operandi to take out, and will permanently stay in the patient body.In addition, present sealed seed source medicine dispatches from the factory and is a medication unit, and when carrying out interior radiotherapy, the doctor selects to put into one or more medication unit according to the practical situation of focus, thereby will stay one or more Titanium shells in patient body.
The utility model content
The technical problems to be solved in the utility model is to place radiopharmaceutical Titanium shell and still stay in the human body after finishing the course for the treatment of in order to overcome in the prior art, can cause the discomfort on patients ' psychological and the health, and the defective that can not adjust of the medication unit of seed source in a Titanium shell, provide and place radiopharmaceutical carrier in a kind of interior radiotherapy.
This utility model solves above-mentioned technical problem by following technical proposals:
Place radiopharmaceutical carrier in a kind of interior radiotherapy, its characteristics are, it comprises at least one be used to placing radiopharmaceutical medicine carrying body; One is used for the shell of accommodating described medicine carrying body, and an end of this shell is provided with an opening; An and end cap that is used for this opening of sealing; Wherein, at least one in described medicine carrying body, this shell and this end cap made for the medical bio degradation material.The kind of medical bio degradation material comprises at present: degradable poly condensation material and degradable alloy material.Wherein medical bio degradable poly condensation material relates to polylactic acid, Poly-L-lactic acid, copolymer of poly lactic acid, poly-acetic acid fat.Materials can be made sponge strip and live shape and be beneficial to adsorb radiopharmaceuticals.The medical bio degradation material has good degradability and the compatibility; Its difficulty of processing is less, be easy to repeat make, so its structure and shape can arbitrarily change as required; This medical bio degradation material is easy to sterilization.Medical bio degradable alloy relates to magnesium alloy.The component of medical bio degradable magnesium alloy comprises: magnesium, rare earth (its mass ratio＜5%), iridium (its mass ratio＜5%), zirconium (its mass ratio＜5%), magnesium alloy has desirable mechanical support power, biocompatibility, easily degraded, and its degradation product participates in metabolism.
This shell cooperates with this end cap, so that the doctor can place according to the needs of the state of an illness radiopharmaceuticals of various dose (medication unit) in shell, and all radiopharmaceuticals are placed in the shell, can not cause increase dosage, the situation that shell quantity also increases has thereupon alleviated patient's health and psychological burden.Wherein, the radiopharmaceutical consumption that carries at the medicine carrying body is a medication unit.Reach the purpose of above-mentioned adjustment medication unit by the quantity that changes seed source in the shell.
Above-mentioned radiopharmaceuticals can be by applying or being attached on this medicine carrying body by biological glue.
In addition, the degradation speed of above-mentioned medicine carrying body, shell and this end cap should be equal to or less than this radiopharmaceutical speed that partly declines.Those skilled in the art can select the suitable medical bio degradation material of degradation speed according to the radiopharmaceutical half-life that the medicine carrying body carries.For example: when adopting medical bio degradable poly condensation material, because its degradation time is about 9 months, then can adopt the half-life is that 60 days I125 is as radiopharmaceuticals.Same because the degradation time of magnesium alloy is 1～3 month, its also applicable I125 as radiopharmaceuticals.Described magnesium alloy is the commercially available prod, does not repeat them here.
Wherein, this shell is the column structure of hollow, and the cross section of this column structure can be circle or polygon.Described polygon is rectangle, pentagon or hexagon etc.
Wherein, this shell is the rectangular column structure of cross section, and the seamed edge of this column structure is smooth transition.When adopting cross section to be polygonal shell, its seamed edge also can play certain effect that shell rolls that prevents.
Wherein, this medicine carrying body is column, lamellar or spherical.
Wherein, described medical bio degradation material is magnesium alloy materials or medical bio degradable poly condensation material.
Wherein, the outer surface of this shell is provided with skid resistant course.Described skid resistant course can prevent effectively that shell from moving because of the contraction of internal organs or muscle at inside of human body, reaches the effectively purpose for the treatment of of accurate location.
Wherein, described skid resistant course is dentation screw thread or point-like projection.
Wherein, this opening and these end cap surfaces opposite to each other are respectively equipped with adaptive screw thread, and this end cap and this opening are threaded connection.The mode that is threaded can guarantee that the seed source in the shell is sealed effectively, prevents that radiopharmaceuticals leaks in transportation and operation process.
Wherein, the outside of this opening is provided with an annular breach, and the edge of this end cap is provided with an annular flange flange adaptive with this annular breach, and this end cap and this opening are engagement connection.The mode of engagement connection can guarantee that the seed source in the shell is sealed effectively, prevents that radiopharmaceuticals leaks in transportation and operation process.
Wherein, be provided with biological glue between this opening and this end cap.This biological glue can further seal the bonding strength that improves simultaneously end cap and shell to the opening part of this shell, improves the safety in seed source.Those skilled in the art can adopt biological glue common in the medical field, do not repeat them here.
In this utility model, but above-mentioned optimum condition combination in any on the basis that meets this area general knowledge namely gets each preferred embodiment of this utility model.
Positive progressive effect of the present utility model is: place radiopharmaceutical carrier in the interior radiotherapy of the present utility model and also degrading gradually when radiopharmaceuticals is positioned at affected area to discharge ray, this carrier continued degraded until disappear after the release of medicine lonizing radiation was complete in human body.And, can increase and decrease arbitrarily according to the needs for the treatment of the quantity of seed source (being attached with radiopharmaceutical medicine carrying body) in being somebody's turn to do in the radiotherapy in the shell of the radiopharmaceutical carrier of placement, the adjustment of medication unit is flexible, can not increase yet and implant focus number of times and shell quantity, accelerated operative speed, alleviated in the operation in patients and the burden of postoperative.
Description of drawings
Fig. 1 is the structural representation of placing radiopharmaceutical carrier in the interior radiotherapy in this utility model one preferred embodiment.
Fig. 2 is another structural representation of placing radiopharmaceutical carrier in the interior radiotherapy of the present utility model.
The specific embodiment
Provide this utility model preferred embodiment below in conjunction with accompanying drawing, to describe the technical solution of the utility model in detail.
As shown in Figure 1, place radiopharmaceutical carrier in the interior radiotherapy in the present embodiment and comprise that a cross section is the shell 1 of circular column, the end of this shell 1 is hemispherical, thereby reduces the stimulation of 1 pair of focus surrounding tissue of shell.The other end of this shell 1 is provided with an opening.Place radiopharmaceutical carrier in being somebody's turn to do in the radiotherapy and comprise that also one is used for the end cap 2 of this opening of sealing, the closing end of this end cap 2 also presents hemispherical, reduces it to the stimulation of focus surrounding tissue.Outer peripheral face at opening is provided with a ring v notch v 11, is provided with the adaptive annular flange flange 21 of a circle and annular breach 11 at the inner peripheral surface of end cap 2, and annular flange flange 21 engages with ring-type breach 11 when end cap 2 is connected with shell 1.
In the present embodiment, this shell 1 and end cap 2 all adopt the medical bio degradation material to make, and the speed of its degraded is slower than its inner accommodating radiopharmaceutical speed that partly declines.
The cross section that shell adopts in the present embodiment also can be made into the column structure that cross section is rectangle for the circular column structure.As shown in Figure 2, the structure of the end cap 2 ' on the shell 1 ' of the column structure of rectangle and the opening on the shell 1 ' are adaptive.
Placing radiopharmaceutical carrier in being somebody's turn to do in the radiotherapy also comprises be used to carrying radiopharmaceutical medicine carrying body 3.This medicine carrying body 3 adopts the medical bio degradation material identical with shell 1 to make, and the speed of its degraded is also slow than the radiopharmaceutical speed that partly declines of carry.This medicine carrying body 3 is spherical in the present embodiment.Certainly, this medicine carrying body also can be made into column or lamellar 3 ' (see figure 2).
Although more than described the specific embodiment of the present utility model, it will be understood by those of skill in the art that these only illustrate, protection domain of the present utility model is limited by appended claims.Those skilled in the art can make various changes or modifications to these embodiments under the prerequisite that does not deviate from principle of the present utility model and essence, but these changes and modification all fall into protection domain of the present utility model.
Claims (10)
1. place radiopharmaceutical carrier in one kind in the radiotherapy, it is characterized in that, it comprises at least one be used to placing radiopharmaceutical medicine carrying body; One is used for the shell of accommodating described medicine carrying body, and an end of this shell is provided with an opening; An and end cap that is used for this opening of sealing; Wherein, at least one in described medicine carrying body, this shell and this end cap made for the medical bio degradation material.
2. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 1, it is characterized in that, this shell is the column structure of hollow, the rounded or polygon of the cross section of the shell of this column structure.
3. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 2, it is characterized in that, this shell is the rectangular column structure of cross section, and the seamed edge of this column structure is smooth transition.
4. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 1, it is characterized in that, this medicine carrying body is column, lamellar or spherical.
5. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 1, it is characterized in that, this medical bio degradation material is magnesium alloy materials or medical bio degradable poly condensation material.
6. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 1, it is characterized in that, the outer surface of this shell is provided with skid resistant course.
7. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 6, it is characterized in that, this skid resistant course is dentation screw thread or point-like projection.
8. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 1, it is characterized in that, this opening and these end cap surfaces opposite to each other are respectively equipped with adaptive screw thread, and this end cap and this opening are threaded connection.
9. place radiopharmaceutical carrier in the interior radiotherapy as claimed in claim 1, it is characterized in that, the outside of this opening is provided with an annular breach, and the edge of this end cap is provided with an annular flange flange adaptive with this annular breach, and this end cap and this opening are engagement connection.
10. as placing radiopharmaceutical carrier in each described interior radiotherapy among the claim 1-9, it is characterized in that, be provided with biological glue between this opening and this end cap.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220149394 CN202637699U (en) | 2012-04-10 | 2012-04-10 | Carrier for placing radioactive drug in internal radiation therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220149394 CN202637699U (en) | 2012-04-10 | 2012-04-10 | Carrier for placing radioactive drug in internal radiation therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202637699U true CN202637699U (en) | 2013-01-02 |
Family
ID=47406885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201220149394 Expired - Fee Related CN202637699U (en) | 2012-04-10 | 2012-04-10 | Carrier for placing radioactive drug in internal radiation therapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202637699U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970522A (en) * | 2017-11-24 | 2018-05-01 | 黑龙江工程学院 | A kind of degradable metal base subcutaneously carries embedding thing of medicine and preparation method thereof |
| CN109529184A (en) * | 2019-01-16 | 2019-03-29 | 北京智博高科生物技术有限公司 | A kind of cartridge clip device and its application method for sealed seed source |
-
2012
- 2012-04-10 CN CN 201220149394 patent/CN202637699U/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970522A (en) * | 2017-11-24 | 2018-05-01 | 黑龙江工程学院 | A kind of degradable metal base subcutaneously carries embedding thing of medicine and preparation method thereof |
| CN109529184A (en) * | 2019-01-16 | 2019-03-29 | 北京智博高科生物技术有限公司 | A kind of cartridge clip device and its application method for sealed seed source |
| CN109529184B (en) * | 2019-01-16 | 2023-04-28 | 北京智博高科生物技术有限公司 | Cartridge clip device for sealing seed source and application method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108136070A (en) | The prophylactic treatment of osteoarthritis after wound | |
| Brook et al. | Pulsed radiofrequency electromagnetic field therapy: a potential novel treatment of plantar fasciitis | |
| US8029478B2 (en) | Implantable device and method for delivering drug depots to a site beneath the skin | |
| CN202637699U (en) | Carrier for placing radioactive drug in internal radiation therapy | |
| Copuroglu et al. | Acute stress disorder and post-traumatic stress disorder following traumatic amputation. | |
| US20160051477A1 (en) | Method for Administering Metformin | |
| Canham | Porous silicon for medical use: from conception to clinical use | |
| EP3137011A1 (en) | Endodontic treatment with long term drug delivery system | |
| CN101507736A (en) | Traditional Chinese medicine preparation for treating senile dementia, ischium lumbar, swollen glands, get-wind or the other rheumatism | |
| CN103768721A (en) | Magnet therapy paster for treating angiitis and manufacturing method of magnet therapy paster | |
| CN104055550B (en) | A kind of inclined-plane band wire holdfast | |
| CN102210905B (en) | Implanted nerve electrical stimulation system with drug release device | |
| CN107301319A (en) | Antibiogics usage assessment of risks system in Pediatric Clinic and scientific research | |
| CN102343038A (en) | Medicament for treating cerebrosis such as hemiplegic cerebral palsy, falling sickness, Parkinson, headache, insomnia and the like | |
| Malek-Ahmadi et al. | Tardive dyskinesia and electroconvulsive therapy | |
| Yadav et al. | Antimicrobial resistance: an emerging threat to public in Nepal | |
| CN203208532U (en) | Rehabilitation belt for department of cardiology | |
| CN102343040A (en) | Drug for treating otitis media, deaf and tinnitus | |
| US20210052907A1 (en) | Antibiotic Wafer | |
| CN106073974A (en) | A kind of spiritual manic person fixes equipment | |
| Banaag et al. | Radionecrosis induced by cardiac imaging procedures: a case study of a 66-year-old diabetic male with several comorbidities | |
| Yu et al. | Parkinson’s Disease | |
| Said et al. | Noninvasive, Wearable, Pulsed Shortwave (Radiofrequency) Therapy for Analgesia following Knee and Hip Arthroplasty: A Case Series | |
| CN203694390U (en) | Sterile seed source chain | |
| CN111643580A (en) | Traditional Chinese medicine composition for treating neuromyelitis optica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130102 Termination date: 20170410 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |